Varicella vaccine for patients using TNF-alfa inhibitors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031210428

Enrollment

Registered

2021-11-16

Start date

2021-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients using TNF-alfa inhibitors

Interventions

Immunization of varicella vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age > 1 year. (2) Patients using TNF-alfa inhibitors (3) Negative or borderline varicella antibody (EIA-IgG 500/mm3 PHA stimulation index > 101.6 Serum IgG > 300mg/dL (5) PSL<1mg/day or <2mg/2days (6) Disease activity is stable for more than 6 months.

Exclusion criteria

Exclusion criteria: (1) Patients using other biological agents. (2) Patients of hematological disease or after bone marrow transplantation. (3) High disease activity. (4) Patients under immunoglobulin replacement.

Design outcomes

Primary

Measure	Time frame
Presence or absence of vaccine strain varicella	—

Secondary

Measure	Time frame
Seropositivity rate after varicella vaccination Other adverse events	—

Contacts

Public ContactKoichi Kamei

Division of Nephrology and Rheumatology, National Center for Child Health and Development

kamei-k@ncchd.go.jp+81-3-5494-7128

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026